Peterson Kristine — SEC insider filings
SEC reporting owner CIK 1508596. 26 insider filings on record with FilingPulse; latest filed 2026-10-20.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2021-02-22 to 2026-10-20. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 20,000 shares, $578,000 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 53.
- Largest priced transaction: sale of 20,000 shares @ $28.90 ($578,000) in ImmunoGen, Inc., filed 2023-12-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ImmunoGen, Inc. (IMGN) | Director | 6 | — | 1 leg · 20,000 sh · $578,000 | 23 |
| Paratek Pharmaceuticals, Inc. (PRTK) | Director | 4 | — | — | 12 |
| ENANTA PHARMACEUTICALS INC (ENTA) | Director | 6 | — | — | 6 |
| AMARIN CORP PLC\UK (AMRN) | Director | 2 | — | — | 4 |
| ArriVent BioPharma, Inc. (AVBP) | Director | 3 | — | — | 3 |
| Immunocore Holdings plc (IMCR) | Director | 3 | — | — | 3 |
| Mineralys Therapeutics, Inc. (MLYS) | Director | 2 | — | — | 2 |
Insider filings — Peterson Kristine
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-20 | 3 | Mineralys Therapeutics, Inc. (MLYS) | Holdings only — no transactions reported | EDGAR |
| 2026-10-20 | 4 | Mineralys Therapeutics, Inc. (MLYS) | Grant/award (A): 12,400 @ $0 · Grant/award (A): 16,600 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 13,562 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Immunocore Holdings plc (IMCR) | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 15,502 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Immunocore Holdings plc (IMCR) | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Immunocore Holdings plc (IMCR) | Grant/award (A): 14,534 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 28,587 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | ImmunoGen, Inc. (IMGN) | Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 74,954 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · +4 more | EDGAR |
| 2023-12-05 | 4 | ImmunoGen, Inc. (IMGN) | Option exercise (M): 10,000 @ $10.10 · Option exercise (M): 10,000 @ $13.07 · Sale (S): 20,000 @ $28.90 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2023-09-21 | 4 | Paratek Pharmaceuticals, Inc. (PRTK) | Disposition to issuer (D): 59,000 · Disposition to issuer (D): 20,000 · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 7,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 5,000 (derivative) · +2 more | EDGAR |
| 2023-09-14 | 4 | ImmunoGen, Inc. (IMGN) | Option exercise (M): 10,000 @ $14.70 · Option exercise (M): 10,000 @ $16.08 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | ImmunoGen, Inc. (IMGN) | Grant/award (A): 13,090 (derivative) @ $0 · Grant/award (A): 19,597 (derivative) @ $0 | EDGAR |
| 2023-03-06 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 10,800 (derivative) @ $0 | EDGAR |
| 2023-02-09 | 4 | Paratek Pharmaceuticals, Inc. (PRTK) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2022-06-29 | 4 | AMARIN CORP PLC\UK (AMRN) | Grant/award (A): 115,919 (derivative) @ $0 · Grant/award (A): 93,750 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | ImmunoGen, Inc. (IMGN) | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 44,000 (derivative) @ $3.37 | EDGAR |
| 2022-03-07 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2022-02-18 | 4 | Paratek Pharmaceuticals, Inc. (PRTK) | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2021-06-17 | 4 | ImmunoGen, Inc. (IMGN) | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 44,000 (derivative) @ $6.77 | EDGAR |
| 2021-06-16 | 4 | AMARIN CORP PLC\UK (AMRN) | Grant/award (A): 45,953 (derivative) @ $0 · Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2021-03-04 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 7,500 (derivative) @ $0 | EDGAR |
| 2021-02-22 | 4 | Paratek Pharmaceuticals, Inc. (PRTK) | Grant/award (A): 9,000 @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-02-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1508596 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs